• Overview of key preclinical proof-of-concept studies demonstrating the amenability of voltage-gated sodium channels (NaV1.7, NaV1.8, NaV1.9) to targeted protein degradation modalities (PROTACs and molecular glues)
• Discussion of differentiating advantages of degrader analgesics over occupancy-based pharmacology
• Discussion of the challenges and opportunities for bringing degrader analgesics to the clinic

New Data